Vytorin(R) (ezetimibe/simvastatin) Versus Zocor(R) (simvastatin) For Patients With High Cholesterol, Data Analysis



In a new analysis presented today VYTORIN(R) (ezetimibe/simvastatin) significantly reduced LDL “bad” cholesterol by an average of 52.5 percent and C-reactive protein (CRP) by an average of 31.0 percent, compared to averages of 38.0 percent and 14.3 percent, respectively, achieved with Zocor(R) (simvastatin) (p




You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply

You must be logged in to post a comment.